Experiments feeding these yeasts to honeybees shows that the presence of these sterols can improve their reproduction,” says APIX Biosciences’ Chairman Thierry Bogaert. “This confirms and extends the ...

Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery (BIOS), today announced the close of a $42 million Series C ...

The securities described above are being offered by Invivyd pursuant to a shelf registration statement on Form S-3 (File No. 333-267643) filed with the U.S. Securities and Exchange Commission (SEC) on ...

CHARLOTTE, N.C., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Hemp Hop, a trusted name in premium hemp products since 2018, has just ...

An adjusted EBITDA margin expected at around 39% by 2030, based on current currency exchange rates. The strategy period includes synergies, as well as significant investments in innovation, commercial ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist, previously approved as IMCIVREE ® by the FDA, the EMA, and UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) for obesity due to ...

Jason Wild, Executive Chairman of TerrAscend, stated, “We believe our shares represent compelling value at current levels, especially in the context of recent federal regulatory momentum. This program ...

INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the ...

For nearly five decades, Glaucoma Research Foundation has harnessed donor support to advance its mission to cure glaucoma—the leading cause of irreversible blindness. With no cure and everyone at risk ...

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative ...

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that European Patent Office ...